We are live on ! Find out more
OM

Opaleye Management Portfolio holdings

AUM $1.1B
1-Year Est. Return 197.64%
This Fund
S&P 500
This Quarter Est. Return
+75.06%
1 Year Est. Return
+197.64%
3 Year Est. Return
+748.31%
5 Year Est. Return
+1,163.14%
10 Year Est. Return
+87,953.74%
AUM
$495M
AUM Growth
+$118M
Cap. Flow
-$4.08M
Cap. Flow %
-0.82%
Top 10 Hldgs %
52.26%
Holding
60
New
16
Increased
13
Reduced
8
Closed
12

Top Buys

Rank Stock Value
1
FBIO icon
Fortress Biotech
FBIO
+$9.48M
2
KNSA icon
Kiniksa Pharmaceuticals
KNSA
+$7.2M
3
BHVN
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
+$6.09M
4
OCUL icon
Ocular Therapeutix
OCUL
+$5.71M
5
CYTK icon
Cytokinetics
CYTK
+$5.68M

Top Sells

Rank Stock Value
1
FTSV
Forty Seven, Inc. Common Stock
FTSV
+$36.8M
2
APTO
Aptose Biosciences, Inc.
APTO
+$6.39M
3
KDMN
Kadmon Holdings, Inc.
KDMN
+$4.83M
4
KALA icon
KALA BIO
KALA
+$4.76M
5
ZYME icon
Zymeworks
ZYME
+$4.72M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TARA icon
1
Protara Therapeutics
TARA
$236M
$64.8M 13.08%
2,208,472
– –
OCUL icon
2
Ocular Therapeutix
OCUL
$2.38B
$49.8M 10.07%
5,984,200
+861,700
+17% +$5.71M
NGNE icon
3
Neurogene
NGNE
$758M
$23.2M 4.69%
70,000
– –
CCXI
4
DELISTED
ChemoCentryx, Inc.
CCXI
$20.8M 4.2%
361,600
– –
ETON icon
5
Eton Pharmaceutcials
ETON
$1.79B
$19.8M 4.01%
3,640,000
– –
APTO
6
DELISTED
Aptose Biosciences, Inc.
APTO
$19.8M 3.99%
6,956
-1,982
-22% -$6.39M
CDXS icon
7
Codexis
CDXS
$182M
$16.1M 3.25%
1,400,000
– –
STXS icon
8
Stereotaxis
STXS
$147M
$15.7M 3.16%
3,511,500
-350,000
-9% -$1.42M
EIDX
9
DELISTED
Eidos Therapeutics, Inc. Common Stock
EIDX
$14.6M 2.96%
315,550
– –
HROW icon
10
Harrow
HROW
$1.44B
$14.1M 2.85%
2,710,000
+210,000
+8% +$1.03M
MYOV
11
DELISTED
Myovant Sciences Ltd.
MYOV
$14.1M 2.84%
682,500
+26,500
+4% +$360K
MGNX icon
12
MacroGenics
MGNX
$260M
$14M 2.83%
501,000
+78,700
+19% +$1.37M
CLDX icon
13
Celldex Therapeutics
CLDX
$3.18B
$13.9M 2.81%
+1,071,000
New +$4.75M
DCPH
14
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
$13.1M 2.64%
222,000
– –
ATXI
15
DELISTED
Avenue Therapeutics, Inc. Common Stock
ATXI
$11.1M 2.25%
920
– –
ODT
16
DELISTED
Odonate Therapeutics, Inc. Common Stock
ODT
$10.6M 2.14%
250,000
-110,000
-31% -$3.56M
FBIO icon
17
Fortress Biotech
FBIO
$93.4M
$10.3M 2.07%
+255,333
New +$9.48M
TGTX icon
18
TG Therapeutics
TGTX
$8.53B
$8.89M 1.8%
456,600
-36,400
-7% -$586K
KNSA icon
19
Kiniksa Pharmaceuticals
KNSA
$6.23B
$8.78M 1.77%
+344,500
New +$7.2M
AVTX icon
20
Avalo Therapeutics
AVTX
$1.08B
$8.77M 1.77%
1,171
+406
+53% +$2.95M
QURE icon
21
uniQure
QURE
$3.44B
$8.55M 1.73%
270,400
+60,400
+29% +$3.57M
BHVN
22
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
$8.36M 1.69%
+114,350
New +$6.09M
XOMA
23
DELISTED
Xoma
XOMA
$8.21M 1.66%
415,380
+28,380
+7% +$623K
CRNX icon
24
Crinetics Pharmaceuticals
CRNX
$9B
$7.63M 1.54%
435,200
+66,450
+18% +$1.13M
CYTK icon
25
Cytokinetics
CYTK
$10.8B
$7.14M 1.44%
+303,050
New +$5.68M
1
2 3

Similar funds

CFO
CVA Family Office Denver, Colorado $1.1B AUM 26.6% 1-Year Est. Return
PFM
Premier Fund Managers Guildford, United Kingdom $1.1B AUM 14.42% 1-Year Est. Return
HBCM
Heron Bay Capital Management Bloomfield Hills, Michigan $1.1B AUM 11.31% 1-Year Est. Return
HAS
HBW Advisory Services Simi Valley, California $1.11B AUM 25.66% 1-Year Est. Return
AI
Aperture Investors New York $1.11B AUM 81.44% 1-Year Est. Return
TPA
Trivium Point Advisory Westport, Connecticut $1.1B AUM 28.81% 1-Year Est. Return
ZDA
Zweig-DiMenna Associates New York $1.1B AUM 171.86% 1-Year Est. Return
NW
Naviter Wealth Little Rock, Arkansas $1.1B AUM 33.28% 1-Year Est. Return

Opaleye Management's Q2 2020 Portfolio in Review

As of Q2 2020, Opaleye Management held 60 positions worth $495M, up 31% from $377M the previous quarter. Its ten largest holdings account for 52% of the portfolio.

Opaleye Management's Q2 2020 filing shows 16 new, 13 increased, 8 reduced and 12 closed positions. Its largest new stake was Fortress Biotech: 255,333 shares worth $10.3M. The largest sale was Forty Seven, Inc. Common Stock, an estimated $36.8M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 98% a quarter earlier.

  • Opaleye Management's largest Q2 2020 buy was Fortress Biotech: 255,333 shares worth $10.3M.
  • Opaleye Management added most to Ocular Therapeutix in Q2 2020, an estimated $5.71M increase.
  • Opaleye Management's biggest Q2 2020 reduction was Aptose Biosciences, Inc., cutting an estimated $6.39M.
  • Opaleye Management fully exited Forty Seven, Inc. Common Stock in Q2 2020, selling an estimated $36.8M.
  • Opaleye Management's ten largest holdings make up 52% of its $495M portfolio in Q2 2020.
  • Opaleye Management opened 16 new positions and closed 12 in Q2 2020.
  • Opaleye Management's portfolio value rose 31% quarter-over-quarter to $495M.

Based on Opaleye Management's 13F filing for Q2 2020, filed 14 Aug 2020.